{"protocolSection":{"identificationModule":{"nctId":"NCT02270736","orgStudyIdInfo":{"id":"MRZ60201_3091_1"},"secondaryIdInfos":[{"id":"2013-004532-30","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"},"briefTitle":"Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability","officialTitle":"Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Children and Adolescents (2-17 Years) With Chronic Troublesome Sialorrhea Associated With Neurological Disorders, and/or Intellectual Disability","acronym":"SIPEXI"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-02-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-02-23","type":"ACTUAL"},"completionDateStruct":{"date":"2019-05-07","type":"ACTUAL"},"studyFirstSubmitDate":"2014-10-17","studyFirstSubmitQcDate":"2014-10-17","studyFirstPostDateStruct":{"date":"2014-10-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-12-23","resultsFirstSubmitQcDate":"2020-12-23","resultsFirstPostDateStruct":{"date":"2021-01-20","type":"ACTUAL"},"dispFirstSubmitDate":"2019-02-20","dispFirstSubmitQcDate":"2019-02-20","dispFirstPostDateStruct":{"date":"2019-02-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-08-06","lastUpdatePostDateStruct":{"date":"2021-08-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents naïve to Botulinum neurotoxin treatment and aged 2-17 years."},"conditionsModule":{"conditions":["Chronic Troublesome Sialorrhea","Cerebral Palsy","Stroke","Traumatic Brain Injury","Intellectual Disability"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":256,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Double-blind MP: Placebo (Age 6 to 17 Years)","type":"EXPERIMENTAL","description":"Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.","interventionNames":["Drug: NT 201 Placebo"]},{"label":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","type":"EXPERIMENTAL","description":"Participants will receive NT 201 (up to 2.5 Units per kilogram \\[U/kg\\] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.","interventionNames":["Drug: NT 201"]},{"label":"Open-label, MP: NT 201 (Age 2 to 5 Years)","type":"EXPERIMENTAL","description":"Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.","interventionNames":["Drug: NT 201"]},{"label":"OLEX: NT 201 (Age 6 to 17 Years)","type":"EXPERIMENTAL","description":"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\".","interventionNames":["Drug: NT 201"]},{"label":"OLEX: NT 201 (Age 2 to 5 Years)","type":"EXPERIMENTAL","description":"Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).","interventionNames":["Drug: NT 201"]}],"interventions":[{"type":"DRUG","name":"NT 201 Placebo","description":"NT 201 placebo matching injection.","armGroupLabels":["Double-blind MP: Placebo (Age 6 to 17 Years)"]},{"type":"DRUG","name":"NT 201","description":"NT 201 injection.","armGroupLabels":["Double-blind, MP: NT 201 (Age 6 to 17 Years)","OLEX: NT 201 (Age 2 to 5 Years)","OLEX: NT 201 (Age 6 to 17 Years)","Open-label, MP: NT 201 (Age 2 to 5 Years)"],"otherNames":["IncobotulinumtoxinA","Xeomin","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4","description":"This endpoint was planned to be analyzed in double-blind, MP, 6 to 17 years participants only. uSFR was assessed by weighing of absorbent swabs with safety threads soaked with saliva over 5 minutes and the procedure was repeated after 30 minutes. Salivary flow rate was equal to weight increase of swabs/time of collection. The average of the 2 results for flow rate was calculated. The reduction of measured weight over the study relates to improvement of sialorrhea.","timeFrame":"Baseline and Week 4"},{"measure":"Global Impression of Change Scale (GICS) at Week 4 Assessed by the Carer/Parent(s)","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. The GICS was used to measure the carer's/parent's impression of change due to treatment. The response option was a common 7-point Likert scale, with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).","timeFrame":"Week 4"},{"measure":"Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle","timeFrame":"Baseline up to Week 64"}],"secondaryOutcomes":[{"measure":"Change From Baseline in uSFR at Weeks 8 and 12","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. uSFR was assessed by weighing of absorbent swabs with safety threads soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes. Salivary flow rate was equal to weight increase of swabs/time of collection. The average of the 2 results for flow rate was calculated. The reduction of measured weight over the study relates to improvement of sialorrhea.","timeFrame":"Baseline and Weeks 8 and 12"},{"measure":"GICS at Weeks 8 and 12","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. The GICS was used to measure the carer's/parent's impression of change due to treatment. The response option was a common 7-point Likert scale with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).","timeFrame":"Weeks 8 and 12"},{"measure":"Occurrence of Treatment Emergent Adverse Events of Special Interest (AESI) Overall and by Injection Cycle","timeFrame":"Baseline up to Week 64"},{"measure":"Occurrence of Treatment Emergent Serious Adverse Events (TESAEs) Overall and by Injection Cycle","timeFrame":"Baseline up to Week 64"},{"measure":"Occurrence of TEAEs Related to Treatment as Assessed by the Investigator Overall and by Injection Cycle","timeFrame":"Baseline up to Week 64"},{"measure":"Occurrence of TEAEs Leading to Discontinuation Overall and by Injection Cycle","timeFrame":"Baseline up to Week 64"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female child/adolescent age 2-17 years.\n* Any neurological disorder (e.g. cerebral palsy or traumatic brain injury) and/or intellectual disability associated with chronic troublesome sialorrhea for at least 3 months up to the screening. In subjects with intellectual disability (ID) without neurological disorders, a diagnosis of ID by a specialist, e.g. pediatrician or by a center for developmental medicine is required for inclusion.\n* Severe drooling (modified Teacher´s Drooling Scale \\[mTDS\\] ≥ 6; clothing occasionally becomes damp) as rated by the investigator.\n* Parental consent and the subject's oral or written assent as the subject is able to provide.\n\nExclusion Criteria:\n\n* Chronic troublesome sialorrhea not related to neurological disorders and/or intellectual disability.\n* Body weight \\< 12 kg.\n* Pharmacological treatment for sialorrhea or concomitant medication known to influence sialorrhea strongly (e.g. anticholinergics with exception of locally applied or short acting drugs used under general anesthesia) within 45 days before baseline and during the entire study period.\n* Any previous known or suspected hypersensitivity to Botulinum toxin.\n* Aspiration pneumonia within 6 month before screening.\n* Any previous treatment with Botulinum toxin for any body region during the year before screening or within the screening period\n* Prior, concomitant or planned surgery or irradiation to head and neck to control sialorrhea (including salivary gland surgery or salivary gland irradiation) within one year before screening or planned for any part of the entire study period.\n* Concurrent diseases, including hematological, hepatic, renal, gastrointestinal, endocrine, pulmonary, musculoskeletal, or psychiatric diseases or conditions, which in the judgment of the investigator would put the subject at risk while in the study, could influence the results of the study, or negatively impact the subject's ability to participate in the study.\n* Extremely poor dental and/or oral condition that might preclude safe study participation by the judgment of the investigator.\n* Nursing mother or pregnant female subject.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Merz Medical Expert","affiliation":"Merz Pharmaceuticals GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Merz Investigational Site #9950003","city":"Kobuleti","zip":"6200","country":"Georgia","geoPoint":{"lat":41.82,"lon":41.77528}},{"facility":"Merz Investigational Site #9950001","city":"Tbilisi","zip":"0159","country":"Georgia","geoPoint":{"lat":41.69411,"lon":44.83368}},{"facility":"Merz Investigational Site #9950002","city":"Tbilisi","zip":"0159","country":"Georgia","geoPoint":{"lat":41.69411,"lon":44.83368}},{"facility":"Merz Investigational Site #0360017","city":"Balassagyarmat","zip":"2660","country":"Hungary","geoPoint":{"lat":48.07296,"lon":19.29614}},{"facility":"Merz Investigational Site #0360013","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site # 0360014","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site # 0360015","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site #0360018","city":"Budapest","zip":"1146","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site #0360016","city":"Szombathely","zip":"9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"facility":"Merz Investigational Site #0480092","city":"Bialystok","zip":"15-274","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Merz Investigational Site #0480090","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Merz Investigational Site #0480076","city":"Katowice","zip":"40-954","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"Merz Investigational Site #0480059","city":"Krakow","zip":"30-359","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #0480060","city":"Wiazowna","zip":"05-462","country":"Poland","geoPoint":{"lat":52.17056,"lon":21.2915}},{"facility":"Merz Investigational Site #0070016","city":"Kazan","zip":"420012","country":"Russian Federation","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Merz Investigational Site # 0070288","city":"Kemerovo","zip":"650066","country":"Russian Federation","geoPoint":{"lat":55.33333,"lon":86.08333}},{"facility":"Merz Investigational Site #0070290","city":"Khabarovsk","zip":"680038","country":"Russian Federation","geoPoint":{"lat":48.48271,"lon":135.08379}},{"facility":"Merz Investigational # 0070017","city":"Saint Petersburg","zip":"194100","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Merz Investigational Site #0070013","city":"Smolensk","zip":"214018","country":"Russian Federation","geoPoint":{"lat":54.7818,"lon":32.0401}},{"facility":"Merz Investigational Site # 070019","city":"Stavropol","zip":"355029","country":"Russian Federation","geoPoint":{"lat":45.0428,"lon":41.9734}},{"facility":"Merz Investigational Site #0070300","city":"Tomsk","zip":"634052","country":"Russian Federation","geoPoint":{"lat":56.49771,"lon":84.97437}},{"facility":"Merz Investigational Site #0070301","city":"Yekaterinburg","zip":"620149","country":"Russian Federation","geoPoint":{"lat":56.8519,"lon":60.6122}},{"facility":"Merz Investigational Site #3810001","city":"Belgrade","zip":"11040","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Merz Investigational Site #3800001","city":"Dnipropetrovsk","zip":"49027","country":"Ukraine","geoPoint":{"lat":48.4593,"lon":35.03864}},{"facility":"Merz Investigational Site #3800012","city":"Ivano-Frankivsk","zip":"76014","country":"Ukraine","geoPoint":{"lat":48.9215,"lon":24.70972}},{"facility":"Merz Investigational Site #3800005","city":"Kharkiv","zip":"61068","country":"Ukraine","geoPoint":{"lat":49.98081,"lon":36.25272}},{"facility":"Merz Investigational Site #3800007","city":"Kharkiv","zip":"61153","country":"Ukraine","geoPoint":{"lat":49.98081,"lon":36.25272}},{"facility":"Merz Investigational Site #3800013","city":"Kherson","zip":"73010","country":"Ukraine","geoPoint":{"lat":46.65581,"lon":32.6178}},{"facility":"Merz Investigational site #3800003","city":"Odesa","zip":"65012","country":"Ukraine","geoPoint":{"lat":46.47747,"lon":30.73262}},{"facility":"Merz Investigational Site #3800009","city":"Ternopil","zip":"46020","country":"Ukraine","geoPoint":{"lat":49.55589,"lon":25.60556}},{"facility":"Merz Investigational Site #3800011","city":"Zaporizhzhya","zip":"69063","country":"Ukraine","geoPoint":{"lat":50.60727,"lon":31.78792}}]},"referencesModule":{"references":[{"pmid":"34341153","type":"RESULT","citation":"Berweck S, Bonikowski M, Kim H, Althaus M, Flatau-Baque B, Mueller D, Banach MD. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI. Neurology. 2021 Oct 4;97(14):e1425-e1436. doi: 10.1212/WNL.0000000000012573."},{"pmid":"36136523","type":"DERIVED","citation":"Berweck S, Banach M, Gaebler-Spira D, Chambers HG, Schroeder AS, Geister TL, Althaus M, Hanschmann A, Vacchelli M, Bonfert MV, Heinen F, Dabrowski E. Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis. Toxins (Basel). 2022 Aug 25;14(9):585. doi: 10.3390/toxins14090585."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 281 participants were screened, out of which 256 participants were enrolled/randomized into the study. Of these 256 participants, 255 participants received the study treatment. A total of 247 participants who completed the Main Period (MP) entered the Open-label Extension Period (OLEX) of the study.","recruitmentDetails":"The study was conducted at 28 investigational sites in Georgia, Hungary, Poland, Russia, Serbia, and Ukraine.","groups":[{"id":"FG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"FG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 Units per kilogram \\[U/kg\\] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"FG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"FG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"FG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"periods":[{"title":"Main Period (MP) (up to 16 Weeks)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"148"},{"groupId":"FG002","numSubjects":"36"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"148"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"146"},{"groupId":"FG002","numSubjects":"34"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Randomized, not Treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"OLEX Period (up to 48 Weeks)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","comment":"2 participants from MP did not enter OLEX due to withdrawal of consent.","numSubjects":"214"},{"groupId":"FG004","comment":"1 participant from MP did not enter OLEX due to adverse event.","numSubjects":"33"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"189"},{"groupId":"FG004","numSubjects":"33"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"25"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The safety evaluable set (SES) (MP) is the subset of all participants who received study medication (NT 201 or placebo) during the MP of the study.","groups":[{"id":"BG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"BG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"BG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"255"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"In utero","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"Preterm newborn infants (gestational age < 37 wks)","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"Newborns (0-27 days)","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"Infants and toddlers (28 days-23 months)","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"Children (2-11 years)","categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"179"}]}]},{"title":"Adolescents (12-17 years)","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"76"}]}]},{"title":"Adults (18-64 years)","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"From 65-84 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]},{"title":"85 years and over","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"95"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"160"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"255"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeter (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"135.3","spread":"16.92"},{"groupId":"BG001","value":"132.8","spread":"17.15"},{"groupId":"BG002","value":"101.1","spread":"8.09"},{"groupId":"BG003","value":"129.1","spread":"19.64"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30.8","spread":"11.67"},{"groupId":"BG001","value":"28.8","spread":"11.48"},{"groupId":"BG002","value":"15.7","spread":"3.00"},{"groupId":"BG003","value":"27.6","spread":"11.78"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram per square meter (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16.4","spread":"3.65"},{"groupId":"BG001","value":"15.8","spread":"3.25"},{"groupId":"BG002","value":"15.3","spread":"1.85"},{"groupId":"BG003","value":"15.9","spread":"3.23"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4","description":"This endpoint was planned to be analyzed in double-blind, MP, 6 to 17 years participants only. uSFR was assessed by weighing of absorbent swabs with safety threads soaked with saliva over 5 minutes and the procedure was repeated after 30 minutes. Salivary flow rate was equal to weight increase of swabs/time of collection. The average of the 2 results for flow rate was calculated. The reduction of measured weight over the study relates to improvement of sialorrhea.","populationDescription":"The full analysis set (FAS) is identical to the subset of participants in the SES (MP) where subset of all participants received study medication (NT 201 or placebo) during the MP of the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"gram per minute (g/min)","timeFrame":"Baseline and Week 4","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 Units per kilogram \\[U/kg\\] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.015"},{"groupId":"OG001","value":"-0.14","spread":"0.012"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Least square mean (LS-Mean) is from a mixed model repeated measurement (MMRM) analysis with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline uSFR score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"= 0.0012","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"-0.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.1","ciUpperLimit":"-0.03","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.019"}]},{"type":"PRIMARY","title":"Global Impression of Change Scale (GICS) at Week 4 Assessed by the Carer/Parent(s)","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. The GICS was used to measure the carer's/parent's impression of change due to treatment. The response option was a common 7-point Likert scale, with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).","populationDescription":"The FAS is identical to the subset of participants in the SES (MP) where subset of all participants received study medication (NT 201 or placebo) during the MP of the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.104"},{"groupId":"OG001","value":"0.91","spread":"0.075"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"LS-Mean is from a MMRM analysis model with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline Modified Teacher Drooling Scale (mTDS) score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"= 0.032","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"0.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.02","ciUpperLimit":"0.53","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.127"}]},{"type":"PRIMARY","title":"Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle","populationDescription":"SES: subset of all participants who received study medication (NT 201 or placebo) during MP or (NT 201) during OLEX of study. \"n\" is number of participants evaluable for this measure at a given time period and who were included in the assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Week 64","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"OG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"classes":[{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"92"},{"groupId":"OG004","value":"15"}]}]},{"title":"First injection cycle (MP)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"5"}]}]},{"title":"Second injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"7"}]}]},{"title":"Third injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"5"}]}]},{"title":"Fourth injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in uSFR at Weeks 8 and 12","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. uSFR was assessed by weighing of absorbent swabs with safety threads soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes. Salivary flow rate was equal to weight increase of swabs/time of collection. The average of the 2 results for flow rate was calculated. The reduction of measured weight over the study relates to improvement of sialorrhea.","populationDescription":"The FAS is identical to the subset of participants in the SES (MP) where subset of all participants received study medication (NT 201 or placebo) during the MP of the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"g/min","timeFrame":"Baseline and Weeks 8 and 12","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Change at Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.015"},{"groupId":"OG001","value":"-0.16","spread":"0.012"}]}]},{"title":"Change at Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.016"},{"groupId":"OG001","value":"-0.16","spread":"0.013"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis at Week 8: LS-Mean is from a MMRM analysis with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline uSFR score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"-0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.12","ciUpperLimit":"-0.05","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.019"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis at Week 12: LS-Mean is from a MMRM analysis with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline uSFR score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.14","ciUpperLimit":"-0.06","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.021"}]},{"type":"SECONDARY","title":"GICS at Weeks 8 and 12","description":"This endpoint was analyzed in double-blind, MP, 6 to 17 years participants. The GICS was used to measure the carer's/parent's impression of change due to treatment. The response option was a common 7-point Likert scale with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).","populationDescription":"The FAS is identical to the subset of participants in the SES (MP) where subset of all participants received study medication (NT 201 or placebo) during the MP of the study.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Weeks 8 and 12","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.096"},{"groupId":"OG001","value":"0.94","spread":"0.068"}]}]},{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.111"},{"groupId":"OG001","value":"0.87","spread":"0.073"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis at Week 8: LS-Mean is from a MMRM analysis model with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline mTDS score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0008","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.17","ciUpperLimit":"0.63","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.116"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis at Week 12: LS-Mean is from a MMRM analysis model with treatment group, pooled investigation sites, and age groups as fixed factors, visit\\*treatment as interaction term, visit as repeated factor, and baseline mTDS score as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"=0.0026","statisticalMethod":"MMRM","paramType":"Least square mean (LS-mean) difference","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.14","ciUpperLimit":"0.66","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.132"}]},{"type":"SECONDARY","title":"Occurrence of Treatment Emergent Adverse Events of Special Interest (AESI) Overall and by Injection Cycle","populationDescription":"SES: subset of all participants who received study medication (NT 201 or placebo) during MP or (NT 201) during OLEX of study. \"n\" is number of participants evaluable for this measure at a given time period and who were included in the assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Week 64","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"OG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"classes":[{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}]}]},{"title":"First injection cycle (MP)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Second injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]},{"title":"Third injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Fourth injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Treatment Emergent Serious Adverse Events (TESAEs) Overall and by Injection Cycle","populationDescription":"SES: subset of all participants who received study medication (NT 201 or placebo) during MP or (NT 201) during OLEX of study. \"n\" is number of participants evaluable for this measure at a given time period and who were included in the assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Week 64","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"OG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"classes":[{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"}]}]},{"title":"First injection cycle (MP)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Second injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]},{"title":"Third injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"}]}]},{"title":"Fourth injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Occurrence of TEAEs Related to Treatment as Assessed by the Investigator Overall and by Injection Cycle","populationDescription":"SES: subset of all participants who received study medication (NT 201 or placebo) during MP or (NT 201) during OLEX of study. \"n\" is number of participants evaluable for this measure at a given time period and who were included in the assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Week 64","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"OG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"classes":[{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"0"}]}]},{"title":"First injection cycle (MP)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Second injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"}]}]},{"title":"Third injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"}]}]},{"title":"Fourth injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Occurrence of TEAEs Leading to Discontinuation Overall and by Injection Cycle","populationDescription":"SES: subset of all participants who received study medication (NT 201 or placebo) during MP or (NT 201) during OLEX of study. \"n\" is number of participants evaluable for this measure at a given time period and who were included in the assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Week 64","groups":[{"id":"OG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm."},{"id":"OG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks."},{"id":"OG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\"."},{"id":"OG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"classes":[{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}]}]},{"title":"First injection cycle (MP)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Second injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"214"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Third injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"205"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Fourth injection cycle (OLEX)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"193"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline up to Week 64","description":"The investigator asked the participant for adverse events (AEs) systematically at each visit.","eventGroups":[{"id":"EG000","title":"Double-blind MP: Placebo (Age 6 to 17 Years)","description":"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes were matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.","deathsNumAffected":0,"deathsNumAtRisk":72,"seriousNumAffected":1,"seriousNumAtRisk":72,"otherNumAffected":3,"otherNumAtRisk":72},{"id":"EG001","title":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.","deathsNumAffected":0,"deathsNumAtRisk":148,"seriousNumAffected":0,"seriousNumAtRisk":148,"otherNumAffected":3,"otherNumAtRisk":148},{"id":"EG002","title":"Open-label, MP: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":1,"seriousNumAtRisk":35,"otherNumAffected":2,"otherNumAtRisk":35},{"id":"EG003","title":"OLEX: NT 201 (Age 6 to 17 Years)","description":"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm consisted of participants who participated in MP arms \"Double-blind, MP: placebo (age 6 to 17 years)\" and \"Double-blind, MP: NT 201 (age 6 to 17 years)\".","deathsNumAffected":0,"deathsNumAtRisk":214,"seriousNumAffected":8,"seriousNumAtRisk":214,"otherNumAffected":34,"otherNumAtRisk":214},{"id":"EG004","title":"OLEX: NT 201 (Age 2 to 5 Years)","description":"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).","deathsNumAffected":0,"deathsNumAtRisk":33,"seriousNumAffected":0,"seriousNumAtRisk":33,"otherNumAffected":12,"otherNumAtRisk":33}],"seriousEvents":[{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Functional gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Gastroenteritis rotavirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Foreign body in gastrointestinal tract","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Limb deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]},{"term":"Gastric operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":33}]}],"otherEvents":[{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":72},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":148},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG003","numEvents":16,"numAffected":13,"numAtRisk":214},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":33}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":13,"numAffected":12,"numAtRisk":214},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":33}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":214},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":33}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":214},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":33}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":214},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":33}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":72},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":214},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":33}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected."},"pointOfContact":{"title":"Public Disclosure Manager","organization":"Merz Pharmaceuticals GmbH","email":"clinicaltrials@merz.com","phone":"+49 69 1503 1"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-06-16","uploadDate":"2020-11-24T10:31","filename":"Prot_001.pdf","size":3650566},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-06-21","uploadDate":"2020-11-24T10:30","filename":"SAP_000.pdf","size":1650896}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Romania"]},"conditionBrowseModule":{"meshes":[{"id":"D000012798","term":"Sialorrhea"},{"id":"D000001930","term":"Brain Injuries"},{"id":"D000002547","term":"Cerebral Palsy"},{"id":"D000070642","term":"Brain Injuries, Traumatic"},{"id":"D000008607","term":"Intellectual Disability"},{"id":"D000009422","term":"Nervous System Diseases"}],"ancestors":[{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000006259","term":"Craniocerebral Trauma"},{"id":"D000020196","term":"Trauma, Nervous System"},{"id":"D000014947","term":"Wounds and Injuries"},{"id":"D000001925","term":"Brain Damage, Chronic"},{"id":"D000019954","term":"Neurobehavioral Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000065886","term":"Neurodevelopmental Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000012466","term":"Salivary Gland Diseases"},{"id":"D000009059","term":"Mouth Diseases"},{"id":"D000009057","term":"Stomatognathic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M12847","name":"Paralysis","relevance":"LOW"},{"id":"M5486","name":"Cerebral Palsy","asFound":"Cerebral Palsy","relevance":"HIGH"},{"id":"M11279","name":"Intellectual Disability","asFound":"Intellectual Disability","relevance":"HIGH"},{"id":"M4897","name":"Brain Injuries","asFound":"Brain Injury","relevance":"HIGH"},{"id":"M628","name":"Brain Injuries, Traumatic","asFound":"Traumatic Brain Injury","relevance":"HIGH"},{"id":"M15294","name":"Sialorrhea","asFound":"Sialorrhea","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"},{"id":"M9039","name":"Craniocerebral Trauma","relevance":"LOW"},{"id":"M21713","name":"Trauma, Nervous System","relevance":"LOW"},{"id":"M4892","name":"Brain Damage, Chronic","relevance":"LOW"},{"id":"M21516","name":"Neurobehavioral Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M30334","name":"Neurodevelopmental Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M14975","name":"Salivary Gland Diseases","relevance":"LOW"},{"id":"M11709","name":"Mouth Diseases","relevance":"LOW"},{"id":"M11707","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"},{"id":"C000545476","term":"incobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M250251","name":"incobotulinumtoxinA","asFound":"Anxiety Scale","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}